Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?

Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA.

Haematologica. 2013 Jun;98(6):988-92. doi: 10.3324/haematol.2012.079210.

PMID:
23729727
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.

Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA.

Clin J Am Soc Nephrol. 2007 May;2(3):440-4. Epub 2007 Apr 4.

PMID:
17699449
[PubMed - indexed for MEDLINE]
Free Article
3.

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.

PMID:
16112045
[PubMed - indexed for MEDLINE]
4.

Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.

Roth RM, Benson D, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Brodsky SV.

Arch Pathol Lab Med. 2013 Sep;137(9):1304-8. doi: 10.5858/arpa.2012-0159-CR. Review.

PMID:
23991744
[PubMed - indexed for MEDLINE]
5.

Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.

Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N.

Nephrol Dial Transplant. 2012 Mar;27(3):1097-101. doi: 10.1093/ndt/gfr381. Epub 2011 Nov 7.

PMID:
22067518
[PubMed - indexed for MEDLINE]
Free Article
6.

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M.

Ann Intern Med. 2001 May 1;134(9 Pt 1):746-53.

PMID:
11329232
[PubMed - indexed for MEDLINE]
7.

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.

Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kumar SK, Hogan WJ, Gertz MA.

Cancer. 2012 Dec 15;118(24):6105-9. doi: 10.1002/cncr.27660. Epub 2012 Jun 15.

PMID:
22707405
[PubMed - indexed for MEDLINE]
Free Article
8.

Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.

Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M; Immunopathology Group of the Italian Society of Nephrology.

Nephrol Dial Transplant. 2008 Mar;23(3):941-51. Epub 2007 Oct 19.

PMID:
17951308
[PubMed - indexed for MEDLINE]
Free Article
9.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

PMID:
9573002
[PubMed - indexed for MEDLINE]
Free Article
10.

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.

Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N.

Nephrol Dial Transplant. 2011 Jun;26(6):2032-6. doi: 10.1093/ndt/gfr067. Epub 2011 May 4.

PMID:
21543655
[PubMed - indexed for MEDLINE]
Free Article
11.

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.

Vesole DH, Pérez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Mayo Clin Proc. 2006 Jul;81(7):880-8.

PMID:
16835967
[PubMed - indexed for MEDLINE]
12.

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.

Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Tan T, Sinha S, Leung N, Kyle RA, Rajkumar SV, Gertz MA.

Am J Hematol. 2011 Mar;86(3):251-5. doi: 10.1002/ajh.21948. Epub 2011 Feb 15.

PMID:
21328431
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
[PubMed - indexed for MEDLINE]
14.

Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.

Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N.

Am J Hematol. 2012 Jan;87(1):51-4. doi: 10.1002/ajh.22202. Epub 2011 Nov 11.

PMID:
22076913
[PubMed - indexed for MEDLINE]
15.

Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.

Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.

Kidney Int. 2003 May;63(5):1868-73.

PMID:
12675865
[PubMed - indexed for MEDLINE]
16.

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK.

Leuk Lymphoma. 2010 Dec;51(12):2181-7. doi: 10.3109/10428194.2010.524329. Epub 2010 Oct 20.

PMID:
20958232
[PubMed - indexed for MEDLINE]
17.

[Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].

Qiu ZX, Wang MJ, Wang LH, Sun YH, Xu WL, Liu W, Ou JP, Dong YJ, Wang WS, Li Y, Yin Y, Liang ZY, Cen XN, Ren HY.

Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):187-90. Chinese.

PMID:
22781604
[PubMed - indexed for MEDLINE]
Free Article
18.

[Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].

Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.

Vnitr Lek. 2009 Nov;55(11):1089-96. Review. Czech.

PMID:
20017442
[PubMed - indexed for MEDLINE]
19.

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.

Br J Haematol. 2007 Oct;139(2):224-33.

PMID:
17897298
[PubMed - indexed for MEDLINE]
20.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk